<DOC>
	<DOCNO>NCT00976573</DOCNO>
	<brief_summary>This randomized phase II trial study well carboplatin , paclitaxel , bevacizumab work give without everolimus treat patient malignant melanoma spread start place body . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , may block ability tumor cell grow spread . Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether combination chemotherapy give together bevacizumab effective without everolimus treat patient metastatic melanoma .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel , Bevacizumab With Without Everolimus Treating Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether sufficient promise impact addition everolimus combination carboplatin , paclitaxel , bevacizumab progression-free survival would recommend test patient metastatic malignant melanoma . Secondary - To estimate confirmed tumor response rate treatment regimen . - To estimate distribution overall survival ( OS ) time treatment regimen . - To assess impact safety profile addition everolimus combination carboplatin , paclitaxel , bevacizumab . OUTLINE : This multicenter study . Patients stratify accord elevate LDH ( upper limit normal ) baseline ( yes v ) , location metastatic disease ( M1a [ skin , subcutaneous tissue , lymph node ] v M1b [ lung ] v M1c [ visceral site ] ) prior chemotherapy metastatic disease ( yes v ) . Patients randomize 1 2 treatment arm . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive bevacizumab intravenously ( IV ) 30-90 minute day 1 15 , paclitaxel IV 60 minute day 1 , 8 , 15 , carboplatin IV 30 minute day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM II : Patients receive bevacizumab , paclitaxel , carboplatin Arm I . Patients also receive everolimus orally ( PO ) daily ( QD ) 3 time weekly . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologic proof stage IV malignant melanoma amenable surgery ; ( biopsy locoregional disease set clinically evident stage IV disease , primary tumor alone qualify ) At one prior chemotherapy base regimen metastatic melanoma ( prior taxanebased regimen allow ) ; note : prior adjuvant nontaxane base chemotherapy and/or adjuvant immunotherapy allow ; limit number prior biologic , immunologic targeted therapy Measurable disease define least one lesion whose long diameter accurately measure &gt; = 2.0 cm chest xray , &gt; = 1.0 cm compute tomography ( CT ) scan , CT component positron emission tomography ( PET ) /CT , magnetic resonance imaging ( MRI ) scan ; note : disease measurable physical examination eligible Life expectancy &gt; = 4 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Absolute neutrophil count ( ANC ) &gt; = 1500/mL Platelets ( PLT ) &gt; = 100,000 x 10^9/L Hemoglobin ( Hgb ) &gt; = 9 g/dL ( patient may transfuse meet requirement ) Total cholesterol = &lt; 300 mg/dL ; ( note : serum level cholesterol triglyceride find elevate may lower antilipid therapy , must document level prior enrollment ) Triglycerides = &lt; 2.5 X upper limit normal ( ULN ) ; ( note : serum level cholesterol triglyceride find elevate may lower antilipid therapy , must document level prior enrollment ) Creatinine = &lt; 1.5 x ULN Total bilirubin = &lt; 1.5 mg/dL ( exception : patient document Gilbert 's syndrome allow participate despite elevated bilirubin ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 2.5 x ULN Alkaline phosphatase = &lt; 2.5 x ULN Urine protein : creatinine ( UPC ) ratio &lt; 1.0 screening OR Urine dipstick proteinuria &lt; 2+ ( patient discover &gt; = 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate = &lt; 1 g protein 24 hour eligible ) Negative pregnancy test do = &lt; 7 day prior registration/randomization , woman childbearing potential Ability understand willingness sign write informed consent document Willing return North Central Cancer Treatment Group ( NCCTG ) institution followup Willing provide mandatory blood sample research purpose Willing follow diet low fat cholesterol take everolimus Willing abstain eating grapefruit drinking grapefruit juice duration study Exclusion Criteria Prior treatment agent disrupt vascular endothelial growth factor ( VEGF ) activity ( i.e. , bevacizumab , VEGFtrap , antiVEGF receptor [ R ] monoclonal antibody [ Mab ] ) target VEGFR ( e.g . sunitinib , sorafenib ) Prior treatment mTOR inhibitor melanoma ( sirolimus , temsirolimus , everolimus ) Brain metastasis per MRI CT time prior registration ; note : patient primary therapy brain metastasis ( i.e . surgical resection , whole brain radiation , stereotactic radiation therapy [ SRT ] even stable ) eligible Other investigational agent = &lt; 4 week prior registration/randomization Chemotherapy treatment = &lt; 3 week prior registration/randomization Any biologic , immunologic target therapy = &lt; 2 week prior registration/randomization Major surgical procedure , open biopsy , significant traumatic injury = &lt; 4 week prior registration/randomization Fine needle aspiration core biopsy = &lt; 7 day prior registration/randomization Planned/or anticipate major surgical procedure course study Other medical condition include limited : History liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis hepatitis B C Active infection require parenteral antibiotic Poorly control high blood pressure ( &gt; =150 mm Hg systolic and/or 100 mmHg diastolic ) despite treatment New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Myocardial infarction unstable angina = &lt; 6 month prior registration/randomization Clinically significant peripheral vascular disease Deep venous thrombosis pulmonary embolus = &lt; 1 year registration/randomization and/or ongoing need fulldose oral parenteral anticoagulation Ongoing antiplatelet treatment lowdose aspirin ( i.e. , aspirin 81 mg orally [ p.o . ] daily ) Active bleed pathological condition carry high risk bleeding ( e.g. , know esophageal varix , etc . ) Serious , nonhealing wound ( include wound heal secondary intention ) , ulcer bone fracture History abdominal fistula , gastrointestinal perforation intraabdominal abscess = &lt; 6 month prior registration/randomization History central nervous system ( CNS ) disease ( e.g. , primary brain tumor , vascular abnormality , etc . ) , clinically significant stroke transient ischemic attack ( TIA ) = &lt; 6 month prior registration/randomization , seizures control standard medical therapy Radiographically document tumor invade major blood vessel History hypertensive crisis hypertensive encephalopathy Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN Severely impair lung function define spirometry diffuse capacity lung carbon monoxide ( DLCO ) 50 % normal predict value and/or 02 saturation 88 % less rest room air A known history human immunodeficiency virus ( HIV ) seropositivity Any follow regimen may harmful develop fetus nursing child : Pregnant woman Nursing woman Men woman reproductive potential use effective birth control method must use highly effective contraception throughout trail 6 month last study treatment Existence peripheral sensory neuropathy &gt; = grade 2 History malignancy = &lt; 5 year exception basal cell squamous cell carcinoma skin , treat local resection , carcinoma situ ( e.g . cervix , breast , prostate , etc . ) = &lt; 4 week since last day adjuvant radiation therapy prior registration = &lt; 2 week since last day palliative radiation therapy ; NOTE : patient &gt; 25 % functional bone marrow irradiate eligible trial Active recent history hemoptysis ( &gt; = 1/2 teaspoon bright red blood per episode ) = &lt; 30 day prior registration Known hypersensitivity component everolimus , bevacizumab , carboplatin , paclitaxel Current use drug know strong inhibitor inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) ; note : agent discontinue , everolimus therapy begin &gt; = 7 day discontinuation agent Positive hepatitis B antigen ( HBsAg ) hepatitis C serology ( HCV ) test Planned immunization attenuate live vaccine = &lt; 7 day prior registration study period ; note : close contact receive attenuated live vaccine avoid treatment everolimus ; example live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , Bacillus CalmetteGu√©rin ( BCG ) , yellow fever , varicella TY21a typhoid vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage IV Skin Melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>